论文部分内容阅读
目的通过检测热休克蛋白90(HSP90)在良、恶性嗜铬细胞瘤(PC)组织中的表达情况,探讨HSP90能否成为一项用于评估嗜铬细胞瘤潜在恶性程度的有效分子标记物。方法选取1986年10月～2006年8月在我院泌尿外科行手术治疗、且有完整的临床、病理和随访资料的嗜铬细胞瘤患者存档石蜡标本38例,其中良性嗜铬细胞瘤(BP)21例,恶性嗜铬细胞瘤(MP)17例。采用免疫组化技术Envision二步法,检测良、恶性嗜铬细胞瘤中HSP90的表达情况。恶性组经首次手术确诊后随访28～179月,良性组经首次手术确诊后随访93～264月。结果在MP组中HSP90的阳性表达率为70.59%,明显高于BP组中阳性表达率28.57%,两组热休克蛋白的表达具有显著的统计学差异(P<0.05)。结论 HSP90有望成为区分嗜铬细胞瘤良恶性的一项指标。
Objective To investigate whether HSP90 can be an effective molecular marker for evaluating the potential malignancy of pheochromocytomas by detecting the expression of HSP90 in benign and malignant pheochromocytoma (PC). Methods 38 cases of pheochromocytoma were enrolled in our hospital from October 1986 to August 2006 with complete clinical, pathological and follow-up data. There were 38 cases of benign pheochromocytoma (BP ) 21 cases, 17 cases of malignant pheochromocytoma (MP). Immunohistochemistry Envision two-step method was used to detect the expression of HSP90 in benign and malignant pheochromocytomas. The malignant group was followed up for 28 ~ 179 months after the first operation. The benign group was followed up for 93 ~ 264 months after the first operation. Results The positive expression rate of HSP90 in MP group was 70.59%, which was significantly higher than that in BP group (28.57%). There was significant difference between the two groups in the expression of heat shock protein (P <0.05). Conclusions HSP90 is expected to be an index to distinguish between benign and malignant pheochromocytomas.